Medical devices are increasingly the targets of cyber thieves looking to get their hands on sensitive information. And the risks are growing rapidly.
Imagine taking a pill with an ingestible sensor that takes measurements and sends information wirelessly to your doctor, or a pill that senses changes in your gut microbiome and adjusts its dose accordingly. Ingestible medical devices promise such applications, and many more, but a big challenge is making their power sources safe for our bodies.
Digital health broke out in 2017. We saw more investment than ever before: Over $4.7 billion flowed into a record number of companies. While these record-breaking investments underscore the enthusiasm for new digital health solutions, another revolution was quietly happening just outside the spotlight.
AbbVie’s investigational JAK1-inhibitor upadacitinib yielded positive top-line results in a Phase III trial as a monotherapy for rheumatoid arthritis patients. But the drug shows that it is still plagued by some safety concerns.
XELJANZ/XELJANZ XR, THE FIRST ORAL JAK INHIBITOR IN THE U.S. FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS, IS NOW APPROVED FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS
A triple-drug focused remedy method may provide an efficient new treatment choice for power lymphocytic leukemia (CLL) that reduces the chance for the lengthy-time period unintended effects skilled with chemotherapy and is given for a restricted time, not as a day by day lifetime drug remedy.
New European research has found that a good social life could lower the risk of developing type 2 diabetes and pre-diabetes.
Over the past decade, the medical device industry has seen a boom in development and innovative ideas. With this innovation came a rise in the costs of medical device products which presents new challenges to buyers. With this in mind, we have compiled a list of 4 tips that could help you in this decision making process.
Cancer cells can lodge in different niches in the body, and the probe follows the spreading cells wherever they go
Pedro Pala, Clinical Trial Supply Manager, Bial, explores the implications of the new EU Clinical Trials Regulation
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.